In a note on October 23, 2019, analysts Owen Bennett and Ryan Tomkins of Jefferies report that Aphria is seeking to divest its 21.5% stake in the Australian supplier Althea.
APHRIA is a BUY with a target price of 11.00.
According to analysts, the presence in Australia and internationally is not as important in the short term since legalization in Canada.
Investors were more interested in its factors when the revenues were not there yet and now they focus more on profitability.
According to the analysts, APHRIA is a BUY with a target price of 11.00.
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best publication on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result.